- Cannabis Global, an innovator in cannabis-infused product science, has launched new coffee and alcohol-replacing products under its Hemp You Can Feel brand since the beginning of the year
- The company promotes the safety and wellness benefits derived from introducing cannabinoids into the food and beverage industry
- A recent report by American Marijuana and a 2018 report by SAMHSA combine to show the importance of using cannabinoid legalization to combat opioid overdoses
- American Marijuana’s study found that of 19 states where medical marijuana is legal, 15 saw marked reductions of opioid prescriptions during the first year after the cannabinoids’ legalization
MCTC Holdings Inc. (OTC: MCTC), now doing business as Cannabis Global, continues to roll out cannabis-infused products designed to revolutionize the food and beverage industry even as news reports continue to highlight the benefits of cannabis in reducing the rate of opioid prescriptions and their potentially harmful addictions.
Cannabis Global’s branded Hemp You Can Feel (TM) Coffee made its debut Feb. 26 in Las Vegas as a science-based infused coffee beverage alternative for advancing wellness-boosting properties, and the company will hold a Hemp You Can Feel Alcohol-Free cocktails launch event for the media in Los Angeles on March 12.
Cannabinoid extracts such as cannabidiol (CBD) and tetrahydrocannabinol (THC) are touted for their ability to deliver pain and anxiety relief through a variety of media, and Cannabis Global’s research continues to explore mechanisms for enhancing their bioavailability.
A recent report by American Marijuana notes that the legalization of medical marijuana throughout the United States has correlated with a reduction in the amount of opioid painkillers being prescribed.
“We’ve selected 19 states where medical marijuana is legal then compared the opioid prescribing rate 1 year before and after medical marijuana was legalized in the state,” the article states (http://cnw.fm/lB9Tw). “Out of the 19 states, 15 have shown a fall of opioid prescribing rate 1 year after legalization of medical marijuana, and only 4 have increased in usage, namely: New Jersey, New Mexico, Michigan, and Arizona.”
The article states Ohio reported the largest drop in the opioid prescription rate, from 82.7 percent to 63.5 percent, measuring the rate of retail opioid prescriptions dispensed per 100 people per year.
Pennsylvania followed Ohio’s 19.2 percent drop with its own 17.8 percent decline in opioid prescriptions, with Arkansas coming in next at 11.8 percent and North Dakota at 11.5 percent. None of the four states with increasing use saw double-digit gains – Michigan, the highest, reported a 9 percent increase while New Jersey was the lowest with a 1.9 percent increase.
The report also noted a study’s findings that Medicaid recipients saw a decrease in opioid prescriptions with the legalization of adult-use recreational marijuana and medical marijuana in their states.
The burgeoning availability of opioid prescription pain relievers such as hydrocodone and oxycodone have been linked to escalating drug addictions during recent decades. The Substance Abuse and Mental Health Services Administration (SAMHSA) reported in its 2018 National Survey on Drug Use and Health that approximately 10 million people aged 12 or older misused opioids in 2018, whether under prescription or in combination with illicit drug, and that about 400,000 died from prescription opioid and related illegal drug overdoses between 1999 and 2017 (http://cnw.fm/EQOx6).
“Can Cannabis solve the opioid crisis? Short answer, to us, is it CAN be a part of the solution to the crisis,” the American Marijuana article states.
Global Cannabis CEO Arman Tabatabaei also touts the safety benefits of using cannabinoids as a replacement for alcohol to avoid the negative effects on behaviors associated with alcohol.
“We believe the uses for this advanced infusion technology are many, especially as a replacement for alcohol in various beverages,” Tabatabaei stated in a December news release (http://cnw.fm/1UIhB).
For more information, visit the company’s website at www.CannabisGlobalInc.com
NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://cnw.fm/MCTC
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
